Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506

Japanese Journal of Clinical Oncology

Volumn 40, Issue 6, 2010, Pages 573-579

  Ishii, Hiroshi ^a   Furuse, Junji ^b   Boku, Narikazu ^c   Okusaka, Takuji ^d   Ikeda, Masafumi ^e   Ohkawa, Shinichi ^f   Fukutomi, Akira ^c   Hamamoto, Yasuo ^g   Nakamura, Kenichi ^h   Fukuda, Haruhiko ^h  

^a CANCER INSTITUTE HOSPITAL   (Japan)

^b KYORIN UNIVERSITY   (Japan)

^c SHIZUOKA CANCER CENTER   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f KANAGAWA CANCER CENTER   (Japan)

^g TOCHIGI CANCER CENTER   (Japan)

^h NATIONAL CANCER CENTER   (Japan)

Author keywords

Chemoradiotherapy; Chemotherapy; Gemcitabine; Locally advanced pancreatic cancer

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL; GEMCITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BILIARY TRACT INFECTION; CANCER FATIGUE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CATHETER INFECTION; CHEMOTHERAPY INDUCED EMESIS; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DUODENUM BLEEDING; FEMALE; HUMAN; HYPERKALEMIA; HYPOCALCEMIA; HYPONATREMIA; LEUKOPENIA; LUNG INFECTION; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PANCREAS CARCINOMA; PHASE 2 CLINICAL TRIAL; SIDE EFFECT; THROMBOCYTOPENIA; ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; MIDDLE AGED; MORTALITY; PAIN ASSESSMENT; PANCREAS TUMOR; PATHOLOGY; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CA-19-9 ANTIGEN; CARCINOMA, ADENOSQUAMOUS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 77953413803     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq011     Document Type: Article

References (31)

1. Ministry of Health, Labour and Welfare. The Dynamic Statistics of the Population in 2005. http://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei05/hyo7.html (1 June 2009, date last accessed).
2. Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA. Combined 5-fluorourail and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865-7.
3. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 1981;48:1705-10.
4. Gastrointestinal Tumor Study Group. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 1988;80:751-5.
5. Burris HA, III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
6. Whittington R, Neuberg D, Tester WJ, Benson AB, Haller DG. Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase 1 Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:227-32.
7. Ishii H, Okada S, Tokuuye K, Nose H, Okusaka T, Yoshimori M, et al. Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma. Cancer 1997;79:1516-20.
8. Rocha Lima CM, Green MR, Rotche R, Miller WH, Jr, Jeffrey GM, Cisar LA, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.
9. Louvet C, Labianca R, Hammel P, Lledo G, Zampino MG, Andre T, et al.; GERCOR, GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
10. Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52.
11. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009;27:3778-85.
12. Manak E, Merkel S, Klein P, Papadopoulos T, Bautz WA, Baum U. Resectability of pancreatic adenocarcinoma: assessment using multidetector-row computed tomography with multiplanar reformations. Abdom Imag 2009;34:75-80.
13. Furuse J, Kinoshita T, Kawashima M, Ishii H, Nagase M, Konishi M, et al. Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma. Cancer 2003;97:1346-52.
14. Morak MJ, Hermans JJ, Smeenk HG, Renders WM, Nuyttens JJ, Kazemier G, et al. Staging for locally advanced pancreatic cancer. Eur J Surg Oncol 2009;35:963-8.
15. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K, Igarashi S. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006;10:511-8.
16. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 1985;3:373-8.
17. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouché O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19:1592-9.
18. Ikeda M, Okada S, Tokuuye K, Ueno H, Okusaka T. A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Br J Cancer 2002;86:1551-4.
19. Okusaka T, Ito Y, Ueno H, Ikeda M, Takezako Y, Morizane C, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer 2004;91:673-7.
20. Crane CH, Abbruzzese JL, Evans DB, Wolff RA, Ballo MT, Delclos M, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002;52:1293-302.
21. McGinn CJ, Zalupski MM. Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials. Int J Radiat Oncol Biol Phys 2003;56:10-5.
22. Loehrer PJ, Powell ME, Cardenes HR, Wagner L, Brell JM, Ramanathan RK, et al.; Eastern Cooperative Oncology Group. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 2008;26: 19087 (20 May supplement; abstract 4506).
23. Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006; (Art. No.: CD002093. doi: 10.1002/14651858.CD002093.pub2).
24. Huguet F, Girard N, Séblain-El Guerche C, Hennequin C, Mornex F, Azria D. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009;27:2269-77.
25. Huguet F, André T, Hammel P, Artru P, Balosso J, Selle F, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007;25:326-31.
26. Krishnan S, Rana V, Janjan NA, Varadhachary GR, Abbruzzese JL, Das P, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007;110:47-55.
27. Kurt E, Kurt M, Kanat O, Cetintas SK, Aygun S, Palazoglu T, et al. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer. Tumori 2006;92:481-6.
28. Brade A, Brierley J, Oza A, Gallinger S, Cummings B, Maclean M, et al. Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study. Int J Radiat Oncol Biol Phys 2007;67:1027-36.
29. Moureau-Zabotto L, Phélip JM, Afchain P, Mineur L, André T, Vendrely V, et al. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study. J Clin Oncol 2008;26:1080-5.
30. Ikeda M, Okusaka T, Ito Y, Ueno H, Morizane C, Furuse J, et al. A phase I trial of S-1 with concurrent radiotherapy for locally advanced pancreatic cancer. Br J Cancer 2007;96:1650-5.
31. Kim HM, Bang S, Park JY, Seong J, Song SY, Chung JB, et al. Phase II trial of S-1 and concurrent radiotherapy in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol 2009;63:535-41.